Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 3/2009 | Stemgent | Series B | 14M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 9/2002 | Glaukos | Series A | 10M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 3/2021 | Amunix | Series B | 117M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/1996 | Corixa | Venture Round | - |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 8/2007 | FlowCardia | Series C | 0 |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 1/2005 | PowerVision | Series A | 4.4M |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 4/2012 | Alcresta | Series A | 10M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 3/2007 | Stromedix | Series A | 1M |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | CVRx | Series D | 65M |
| 1/1996 | ViroPharma | Funding Round | - |
| 7/2011 | PowerVision | Series C | 24M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 12/2007 | Barosense | Series C | 11.2M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 11/2017 | Mavupharma | Series A | 0 |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 12/2017 | Aptinyx | Series B | 70M |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2020 | Inipharm | Series A | 0 |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 3/2019 | Scout Bio | Series B | 20M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 6/2008 | EBR Systems | Series C | 35M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 10/2003 | Cotherix | Series C | 55M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 6/2003 | Xoft | Series B | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 4/2008 | Stromedix | Series B | 25M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 9/2021 | HilleVax | Equity | 135M |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 3/2006 | PowerVision | Series A | 2M |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 12/2003 | FlowCardia | Series B | 12M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
